HUTCHMED (NASDAQ:HCM) Sees Large Volume Increase – What’s Next?

Shares of HUTCHMED (China) Limited (NASDAQ:HCM) saw strong trading volume on Monday . 71,022 shares traded hands during trading, an increase of 3% from the previous session’s volume of 69,081 shares.The stock last traded at $16.03 and had previously closed at $14.99.

Wall Street Analysts Forecast Growth

Separately, StockNews.com lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a research report on Monday, November 18th.

HUTCHMED Price Performance

The business has a 50 day simple moving average of $16.50 and a 200-day simple moving average of $17.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81.

Institutional Investors Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently bought and sold shares of HCM. Jane Street Group LLC grew its holdings in shares of HUTCHMED by 362.2% during the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock valued at $1,305,000 after buying an additional 49,366 shares in the last quarter. State Street Corp boosted its position in HUTCHMED by 0.9% during the 3rd quarter. State Street Corp now owns 349,524 shares of the company’s stock worth $6,826,000 after acquiring an additional 3,078 shares during the period. Rhumbline Advisers grew its stake in HUTCHMED by 8.1% during the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after acquiring an additional 564 shares in the last quarter. M&G PLC increased its holdings in shares of HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company’s stock valued at $5,345,000 after purchasing an additional 132,333 shares during the period. Finally, Blue Trust Inc. lifted its position in shares of HUTCHMED by 638.2% in the third quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after purchasing an additional 3,057 shares in the last quarter. 8.82% of the stock is owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.